High-cost biologics for rheumatoid arthritis- how are payer-led cost-taming strategies impacting brand uptake in the united states?
May 1, 2015, 00:00
10.1016/j.jval.2015.03.961
https://www.valueinhealthjournal.com/article/S1098-3015(15)01018-9/fulltext
Title :
High-cost biologics for rheumatoid arthritis- how are payer-led cost-taming strategies impacting brand uptake in the united states?
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(15)01018-9&doi=10.1016/j.jval.2015.03.961
First page :
A166
Section Title :
Muscular-Skeletal Disorders
Open access? :
No
Section Order :
408